Clinical trial NCT04605120: Allogeinic Bone Paste
Official title: Prospective, Non-randomized, Single Center Clinical Study of Cervical Interbody Fusion Using a Viral-inactivated Allogeneic Graft
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cervical Fusion
Cervical Disc Degeneration
Spinal Fusion
Lead sponsor: Biobank
Sponsor class: INDUSTRY
First posted: 2020-10-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Non-randomized, Single centre
Primary purpose: TREATMENT

Brief summary: This is a prospective, single arm, single center clinical study to evaluate efficacy and safety of a Supercritical CO2 viral-inactivated allogenic bone paste in cervical interbody fusion. Patient eligible for 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft after failure of well-conducted medical treatment will be screened for the study.

Detailed description: Cervical and lumbar fusion are often the best option for various degenerative conditions that do not respond to conservative treatment. Historically, the reference technique for cervical fusion was the use of iliac crest autogenic bone graft (ICBG). However, the use of ICBG has several drawbacks, including the morbidity of the donor site, the increase in operating time and the variable quality of autograft. Alternatives to ICBG for cervical fusion include the use of allografts, graft extensions and osteobiological materials to improve fusion rates.

This is a prospective, single arm, single center clinical study to evaluate efficacy and safety of a Supercritical CO2 viral-inactivated allogenic bone paste in cervical interbody fusion. Patient eligible for 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft after failure of well-conducted medical treatment will be screened for the study.

Subjects will be followed up postoperatively per standard of care at 3 months, 6 months, 12 and 24 months at the clinic. The following outcomes will be measured: overall success, Neck Disability Index (NDI), VAS neck and arm pain, SF-12 health survey, major complications, subsequent surgery rate, and fusion rate on radiological examinations. The primary endpoint is a FDA composite definition of success comprising clinical improvement and absence of major complications and secondary surgery events.

Eligibility criteria: Inclusion Criteria:

1. Male or female, aged ≥18 years old
2. Patient eligible for anterior cervical fusion combined with bone graft after failure of well-conducted medical treatment.
3. Arthrodesis performed on up to 2 levels and fused by one or more plates with an interbody cage on at least one level
4. Radicular signs and symptoms in one or both arms (i.e., pain, paresthesia, or paresis in a specific nerve root distribution) or symptoms and signs of acute or chronic myelopathy
5. X-ray diagnosis of cervical herniated disc and/or osteophyte at 1 or 2 levels depending on clinical signs and symptoms, disc degeneration, trauma without neurological damage
6. Ability and willingness to comply with project requirements
7. Written informed consent given by the subject or the subject's legally authorized representative

Exclusion Criteria:

1. Acute local or systemic infection
2. Women who are pregnant or in a desire to be pregnant or breast-feeding
3. Any contraindication to the proposed surgical procedure
4. Previous cervical surgery (either anterior or posterior)
5. Surgery performed over several operating times
6. Arthrodesis performed posteriorly or involving more than 2 levels or not requiring the use of a bone graft
7. Systemic disease, metabolic bone disease and autoimmune disease.
8. Use of any known drug to potentially interfere with the healing of bones and soft tissues (corticosteroids or immunosuppressive agents...)
9. Any other concomitant medical disease or treatment that could significantly alter the normal healing process as assessed by the investigator
10. Neoplasm of the spine
11. Severe mental or psychiatric disorders
12. Any other condition that, in the investigator's view, would adversely affect patient safety or would not meet the requirements of the protocol

Primary outcomes:
measure: Overall subject study success
timeFrame: 3, 6,12 and 24 months
Secondary outcomes:
measure: Pain and Self reported outcomes
timeFrame: 3, 6, 12 and 24 months
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine
Study officials:
affiliation: Polyclinique Bordeaux Nord Aquitaine - BORDEAUX - FRANCE
name: Jean-Charles LE HUEC, M.D., Prof
role: PRINCIPAL_INVESTIGATOR
References: